Get the Stockscreener App
1.955
1.76%
-0.035
After Hours:
1.99
0.035
+1.79%
Adagene Inc Adr stock is traded at $1.955, with a volume of 648.88K.
It is down -1.76% in the last 24 hours and down -18.20% over the past month.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
See More
Previous Close:
$1.99
Open:
$1.95
24h Volume:
648.88K
Relative Volume:
6.32
Market Cap:
$92.14M
Revenue:
$18.11M
Net Income/Loss:
$-18.95M
P/E Ratio:
-4.4686
EPS:
-0.4375
Net Cash Flow:
-
1W Performance:
-2.25%
1M Performance:
-18.20%
6M Performance:
+34.83%
1Y Performance:
-12.26%
1-Day Range:
$1.90
$2.065
1-Week Range:
$1.85
$2.065
52-Week Range:
$1.325
$3.16
Adagene Inc Adr Stock (ADAG) Company Profile
Compare ADAG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADAG
Adagene Inc Adr
|
1.955 | 93.79M | 18.11M | -18.95M | 0 | -0.4375 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | Leerink Partners | Outperform |
| Jan-31-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-25-21 | Initiated | China Renaissance | Buy |
| Mar-08-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Initiated | Jefferies | Buy |
| Mar-08-21 | Initiated | Morgan Stanley | Overweight |
View All
Adagene Inc Adr Stock (ADAG) Latest News
Weiss Ratings Reaffirms Sell (D-) Rating for Adagene (NASDAQ:ADAG) - MarketBeat
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Short Interest Up 320.2% in September - Defense World
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Sees Significant Increase in Short Interest - MarketBeat
All You Need to Know About Adagene (ADAG) Rating Upgrade to Buy - Yahoo Finance
How sentiment analysis helps forecast Adagene Inc. Depositary ReceiptMarket Growth Review & AI Driven Price Forecasts - newser.com
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Short Interest Update - MarketBeat
Lucid Capital Markets initiates coverage on Adagene stock with Buy rating - Investing.com India
Adagene Inc. Amends Collaboration Agreement with Exelixis to Advance SAFEbody Technology for Cancer Therapy - Quiver Quantitative
Adagene Expands SAFEbody® Collaboration and License - GlobeNewswire
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate - MarketScreener
Breakthrough Cancer Drug Technology: Adagene's 'Invisible' ADC Platform Expands to Third Program - Stock Titan
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Short Interest Down 38.1% in August - Defense World
Using economic indicators to assess Adagene Inc. Depositary Receipt potential2025 Historical Comparison & Verified Short-Term Plans - newser.com
Quantitative breakdown of Adagene Inc. Depositary Receipt recent moveProduct Launch & High Return Trade Opportunity Guides - Newser
Adagene to present new ADG126 clinical data at ASCO-GI - MSN
Using data tools to time your Adagene Inc. Depositary Receipt exit2025 Historical Comparison & Risk Controlled Stock Pick Alerts - Newser
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Drops By 70.6% - MarketBeat
Adagene’s ADG126 to be Highlighted in Two Presentations at - GlobeNewswire
Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China - The Manila Times
Adagene Inc. Showcases ADG126 at CSCO Meeting with Promising Results in Advanced MSS Colorectal Cancer - Quiver Quantitative
30% Response Rate: Adagene's Novel Cancer Drug Shows Promise in Hard-to-Treat Colorectal Cancer Trial - Stock Titan
Former YERVOY developer Axel Hoos joins Adagene as advisor - Investing.com
Adagene Inc. Appoints Dr. Axel Hoos as Executive Advisor to Enhance Immuno-Oncology Initiatives - Quiver Quantitative
Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor - The Manila Times
Former $2.5B Scorpion CEO & YERVOY Developer: Adagene's CTLA-4 Platform Could Transform Cancer Care - Stock Titan
Is Adagene Inc. Depositary Receipt’s growth already priced inJuly 2025 Big Picture & Real-Time Buy Zone Alerts - خودرو بانک
Can Adagene Inc. Depositary Receipt maintain sales growthJuly 2025 Drop Watch & Free Real-Time Market Sentiment Alerts - خودرو بانک
What data driven models say about Adagene Inc. Depositary Receipt’s futureWeekly Stock Recap & Weekly High Momentum Picks - Newser
Adagene to Participate in Two Investor Conferences in September - The Manila Times
Biotech Innovator Adagene Scheduled for Major Wall Street Healthcare Conferences in September 2025 - Stock Titan
Will Adagene Inc. Depositary Receipt see short term momentumTrade Performance Summary & Smart Swing Trading Techniques - Newser
Is Adagene (ADAG) Outperforming Other Medical Stocks This Year? - Yahoo Finance
What moving averages say about Adagene Inc. Depositary ReceiptWeekly Profit Analysis & Daily Chart Pattern Signal Reports - Newser
HC Wainwright Issues Pessimistic Forecast for Adagene (NASDAQ:ADAG) Stock Price - Defense World
How to read the order book for Adagene Inc. Depositary Receipt2025 Volatility Report & Weekly High Conviction Trade Ideas - Newser
Q3 Earnings Forecast for Adagene Issued By Leerink Partnrs - Defense World
H.C. Wainwright lowers Adagene stock price target to $7 on development path clarity - Investing.com
Adagene's 22.4% Surge: Clinical Breakthroughs and Strategic Alliances Ignite Biotech Volatility - AInvest
How institutional ownership impacts Adagene Inc. Depositary Receipt stockPortfolio Gains Report & Risk Controlled Daily Plans - Newser
What indicators show strength in Adagene Inc. Depositary ReceiptJuly 2025 Gainers & Real-Time Buy Zone Alerts - Newser
Published on: 2025-08-12 20:31:18 - Newser
Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
Cancer Drug Breakthrough: Adagene's ADG126 Doubles Standard Survival Rate as Sanofi Backs Development - Stock Titan
Is Adagene Inc. Depositary Receipt still worth holding after the dipFree Low Risk Picks for Daily Trading - Newser
Why Adagene Inc. Depositary Receipt is moving todayStock Price Prediction Using AI Tools - Newser
Q2 Earnings Forecast for Adagene Issued By Leerink Partnrs - Defense World
Using R and stats models for Adagene Inc. Depositary Receipt forecastingFree AI Forecast for Trending Stocks - Newser
Adagene (NASDAQ:ADAG) Raised to “Strong-Buy” at Leerink Partnrs - Defense World
Leerink Partners Begins Coverage on Adagene (NASDAQ:ADAG) - Defense World
Adagene Inc Adr Stock (ADAG) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):